GLP-1 receptor agonists: why is once weekly inferior to once daily?

被引:5
作者
Garber, Alan J. [1 ,2 ]
机构
[1] Baylor Coll Med, Dept Med Biochem & Mol Biol, Houston, TX 77030 USA
[2] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA
关键词
OPEN-LABEL; EXENATIDE; TWICE;
D O I
10.1016/S2213-8587(14)70014-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:266 / 267
页数:2
相关论文
共 6 条
[1]   Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study [J].
Buse, John B. ;
Nauck, Michael ;
Forst, Thomas ;
Sheu, Wayne H-H ;
Shenouda, Sylvia K. ;
Heilmann, Cory R. ;
Hoogwerf, Byron J. ;
Gao, Aijun ;
Boardman, Marilyn K. ;
Fineman, Mark ;
Porter, Lisa ;
Schernthaner, Guntram .
LANCET, 2013, 381 (9861) :117-124
[2]   Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) [J].
Buse, John B. ;
Rosenstock, Julio ;
Sesti, Giorgio ;
Schmidt, Wolfgang E. ;
Montanya, Eduard ;
Brett, Jason H. ;
Zychma, Marcin ;
Blonde, Lawrence .
LANCET, 2009, 374 (9683) :39-47
[3]   Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study [J].
Drucker, Daniel J. ;
Buse, John B. ;
Taylor, Kristin ;
Kendall, David M. ;
Trautmann, Michael ;
Zhuang, Dangliang ;
Porter, Lisa .
LANCET, 2008, 372 (9645) :1240-1250
[4]   Measuring psychological insulin resistance - Barriers to insulin use [J].
Larkin, Mary E. ;
Capasso, Virginia A. ;
Chen, Chien-Lin ;
Mahoney, Ellen K. ;
Hazard, Barbara ;
Cagliero, Enrico ;
Nathan, David M. .
DIABETES EDUCATOR, 2008, 34 (03) :511-517
[5]  
Pratley RE, 2014, LANCET DIABETES ENDO
[6]   Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes A randomized controlled trial exploring weekly, biweekly, and monthly dosing [J].
Rosenstock, Julio ;
Yang, Fred ;
Reusch, Jane ;
Stewart, Murray ;
Bush, Mark .
DIABETES CARE, 2009, 32 (10) :1880-1886